SG Americas Securities LLC Boosts Position in Biogen Inc. $BIIB

SG Americas Securities LLC raised its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 6.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 195,668 shares of the biotechnology company’s stock after buying an additional 11,839 shares during the period. SG Americas Securities LLC owned about 0.13% of Biogen worth $35,872,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in BIIB. Evolve Private Wealth LLC raised its stake in shares of Biogen by 11.1% in the 1st quarter. Evolve Private Wealth LLC now owns 3,536 shares of the biotechnology company’s stock valued at $648,000 after acquiring an additional 353 shares during the period. Guardian Investment Management increased its holdings in Biogen by 1.9% in the 1st quarter. Guardian Investment Management now owns 5,500 shares of the biotechnology company’s stock valued at $1,008,000 after purchasing an additional 100 shares in the last quarter. Quotient Wealth Partners LLC purchased a new position in Biogen in the first quarter valued at about $201,000. BI Asset Management Fondsmaeglerselskab A S lifted its stake in shares of Biogen by 41.6% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 7,886 shares of the biotechnology company’s stock worth $1,446,000 after purchasing an additional 2,315 shares in the last quarter. Finally, Diversified Trust Co acquired a new position in shares of Biogen during the first quarter worth about $232,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

BIIB has been the subject of a number of recent research reports. Canaccord Genuity Group increased their target price on Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research note on Wednesday, April 1st. Citigroup boosted their price target on Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Argus upgraded Biogen to a “hold” rating in a report on Thursday, April 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $225.00 price objective (up from $214.00) on shares of Biogen in a research report on Friday, May 15th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research note on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $217.37.

Biogen Stock Performance

BIIB stock opened at $197.19 on Wednesday. The firm has a market cap of $29.11 billion, a P/E ratio of 21.16 and a beta of 0.20. The stock’s 50 day simple moving average is $191.74 and its 200 day simple moving average is $185.19. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the firm earned $3.02 earnings per share. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts predict that Biogen Inc. will post 13.95 EPS for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.